Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Anastrozole

Study type: Observational

Funder types: Industry

Identifiers

NCT00638391

Ax-003/Arimidex

Ax-003

Details and patient eligibility

About

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Enrollment: 1,600 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion criteria

• None

Trial design

1,600 participants in 1 patient group

1

Description:

all patients treated with Anastrozole

Treatment:

Drug: Anastrozole